Novo Nordisk Rolls Out Multi‑Month Wegovy Subscriptions to Boost Affordability and Challenge Eli Lilly

Novo Nordisk announced a new subscription model for its Wegovy line, offering patients the option to purchase the medication in multi‑month bundles at reduced monthly rates. The program targets both the injectable formulation and the oral pill, with projected annual savings of up to $1,200 for the former and $600 for the latter. By extending the purchase horizon, the company hopes to lower out‑of‑pocket costs and improve adherence among users battling obesity. The launch comes as Novo Nordisk seeks to catch up with Eli Lilly, which has already introduced competitive pricing structures for its own obesity drugs. Industry observers see the subscription strategy as a direct response to growing pressure to make weight‑loss therapies more accessible, especially as demand for such treatments continues to rise. Under the new scheme, patients can lock in a lower per‑dose price by committing to a three‑ to six‑month supply, reducing the frequency of pharmacy visits and simplifying medication management. The company has not disclosed the exact pricing tiers, but the advertised savings suggest a significant discount relative to standard monthly purchases. Analysts anticipate that the subscription model could shift market dynamics, prompting other manufacturers to explore similar offerings. If successful, Novo Nordisk’s approach may broaden the pool of patients who can afford long‑term Wegovy therapy, potentially increasing the drug’s market share in the competitive obesity segment. The initiative also underscores a broader trend of pharmaceutical companies leveraging subscription‑based pricing to address cost concerns while maintaining revenue streams. As insurers and patients weigh the benefits, the impact on overall obesity treatment adoption will become clearer in the coming months.